Robinson, Emily S <br/><br/>
Rapid development of hypertension and proteinuria with cediranib, an oral vascular endothelial growth factor receptor inhibitor.  [electronic resource] 

 -  Clinical journal of the American Society of Nephrology : CJASN  Mar 2010 
 - 477-83 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1555-905X 
<br/><br/><label>Standard No.: </label>10.2215/CJN.08111109  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Administration, Oral<br/>Adult<br/>Age Factors<br/>Aged<br/>Antineoplastic Agents--administration & dosage<br/>Blood Pressure--drug effects<br/>Carcinoma--drug therapy<br/>Chi-Square Distribution<br/>Female<br/>Humans<br/>Hypertension--chemically induced<br/>Middle Aged<br/>Neoplasm Recurrence, Local<br/>Ovarian Neoplasms--drug therapy<br/>Protein Kinase Inhibitors--administration & dosage<br/>Proteinuria--chemically induced<br/>Quinazolines--administration & dosage<br/>Receptors, Vascular Endothelial Growth Factor--antagonists & inhibitors<br/>Risk Assessment<br/>Risk Factors<br/>Severity of Illness Index<br/>Time Factors<br/>Treatment Outcome